Qualigen announces $4.5M private placement of Preferred Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 19 2024
0mins
Qualigen Therapeutics Securities Offering: Qualigen Therapeutics has secured $4.5 million through the sale of 4,500 Series A-2 Preferred Shares, convertible into common shares at a price of $3.64 each.
Closing Details: The offering is expected to finalize around November 19, 2024, pending customary closing conditions, with Univest, LLC serving as the exclusive placement agent.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
